Provided by Tiger Trade Technology Pte. Ltd.

Churchill Capital Corp XI

14.57
+0.50003.55%
Post-market: 14.570.00000.00%19:59 EDT
Volume:1.82M
Turnover:26.21M
Market Cap:811.55M
PE:586.25
High:14.86
Open:14.50
Low:13.88
Close:14.07
52wk High:19.69
52wk Low:10.07
Shares:55.70M
Float Shares:41.40M
Volume Ratio:0.41
T/O Rate:4.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0249
EPS(LYR):0.0249
ROE:--
ROA:--
PB:-57.11
PE(LYR):586.25

Loading ...

Company Profile

Company Name:
Churchill Capital Corp XI
Exchange:
NASDAQ
Establishment Date:
2025
Employees:
- -
Office Location:
640 Fifth Avenue,14th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Directors

Name
Position
Michael Klein
Chairman of the Board and Chief Executive Officer and President
Paul Lapping
Director
Stephen Murphy
Director
William Sherman
Director

Shareholders

Name
Position
Michael Klein
Chairman of the Board and Chief Executive Officer and President
Jay Taragin
Chief Financial Officer